Close Menu

    Subscribe to Updates

    Get the latest creative news from Healthradar about News,Health and Gadgets.

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    What's Hot

    Samsung is slashing prices on our favorite Galaxy Watches – better than Black Friday

    6. Juni 2025

    Outset Medical appoints Renee Gaeta as CFO

    6. Juni 2025

    Hims & Hers Announces Plans to Acquire ZAVA, Accelerating Major European Growth Across the UK, Germany, France, and Ireland

    6. Juni 2025
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram Pinterest Vimeo
    healthradar.nethealthradar.net
    • Home
    • Ai
    • Gadgets
    • Health
    • News
    • Contact Us
    Contact
    healthradar.nethealthradar.net
    Home»Health»Medable Introduces Long-Term Follow-Up Model for Cell & Gene Therapy (CGT) Trials to Reduce Costs and Improve Patient Access
    Health

    Medable Introduces Long-Term Follow-Up Model for Cell & Gene Therapy (CGT) Trials to Reduce Costs and Improve Patient Access

    HealthradarBy Healthradar1. Juni 2025Keine Kommentare3 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email
    Medable Introduces Long-Term Follow-Up Model for Cell & Gene Therapy (CGT) Trials to Reduce Costs and Improve Patient Access
    Share
    Facebook Twitter LinkedIn Pinterest Email


    New digital-first solution enables patient engagement and retention while maintaining scientific rigor throughout 15-year CGT trials

    PALO ALTO, Calif.–(BUSINESS WIRE)–Medable Inc., a leading technology platform provider for decentralized clinical trials, today unveiled its digital-first Long-Term Follow-Up (LTFU) model for cell and gene therapy (CGT) trials. Medable’s platform reduces the burden on patients and sites involved in complex CGT trials and enhances scientific integrity with sustainable data capture across the FDA-required 15-year follow-up period for certain CGTs, including those using genome-editing techniques like CRISPR-Cas9. This extended monitoring period is essential for tracking delayed adverse events, understanding the durability of the therapy, and ensuring the long-term impact on patients, but can add significant hardships.

    CGTs offer transformative potential yet they also require prolonged safety monitoring, often spanning 15 years post-treatment. Traditional models for LTFU impose logistical and financial challenges on participants, contributing to lower participation and high attrition rates over time. According to a 2024 survey conducted by the Emily Whitehead Foundation and Catalyst Healthcare Consulting, 20% of CAR T-cell therapy patients stop participating in long-term follow-up altogether, with 80% of that group ceasing participation at or after five years post-treatment. Distance to sites, lack of awareness about local follow-up options, and burdensome travel are frequently cited as key barriers.

    “Long-term follow-up is essential to ensure the durability and safety of advanced therapies, but the current system isn’t working for patients or sponsors,” said Dr. Pamela Tenaerts, Chief Medical Officer at Medable. “With our new LTFU model, we’re reimagining how post-treatment data is captured – putting patients at the center while ensuring scientific and regulatory rigor.”

    Medable’s digital-first LTFU offering includes:

    • Remote and Hybrid Patient Interaction: Patients can engage in follow-up through flexible virtual, in-person, or blended formats that meet their individual needs and life circumstances.
    • Seamless Transition from Parent Trials: Integrated workflows and data continuity ensure a frictionless handoff from interventional studies to long-term observational follow-up.
    • Patient-First Data Capture and Adherence Monitoring: Leveraging mobile technology, patient reported questionnaires and local healthcare providers to track key endpoints and ensure consistent participation over time.
    • Personalized Patient Communication: Ongoing engagement through tailored content, reminders, and support tools to build trust and maintain long-term connection.

    By embracing a digital, patient-centric approach, Medable’s model addresses key gaps in traditional LTFU execution – improving retention, increasing diversity, and reducing the long-term cost burden for both sponsors and sites.

    Learn more about Medable’s new digital-based LTFU model at American Society of Clinical Oncology’s (ASCO) 2025 Annual Meeting (May 30-June 3) in Chicago at Medable Booth #10105.

    About Medable

    Medable is on a mission to get effective therapies to people faster. Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Awarded Best Digital Health Solution by the Galien Foundation, Medable’s platform has been deployed in nearly 400 trials in 70 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California, and was listed for the second year in a row on the Inc. 5000 in 2024.

    Contacts

    Media Contact:
    Lisa Barbadora, Barbadora INK for Medable

    +1 (610) 420-3413

    lbarbadora@barbadoraink.com / media@medable.com



    Source link

    Access Cell CGT costs FollowUp gene Improve Introduces LongTerm Medable Model Patient Reduce therapy Trials
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleCorti Joins Coalition for Health AI to Advance Responsible and Safe AI in Healthcare
    Next Article US court blocks Trump’s sweeping tariffs
    ekass777x
    Healthradar
    • Website

    Related Posts

    Health

    10 of the most exciting digital health startups of 2024, according to VCs

    6. Juni 2025
    Health

    Inside the Bloodbath at the NIH. Sources say that a climate of fear has spread throughout the agency as the Trump administration takes a hatchet to its core functions.

    5. Juni 2025
    Health

    3-Year Exercise Program Improves Colon Cancer Survival Rates

    4. Juni 2025
    Add A Comment
    Leave A Reply Cancel Reply

    Top Posts

    New surgeon general nominee cofounded a16z backed health app with DOGE operative

    1. Juni 20254 Views

    RadNet Acquires See-Mode Technologies to Bolster AI Capabilities in Ultrasound Imaging

    6. Juni 20253 Views

    Fi’s AI dog collar lets you monitor pet behavior via Apple Watch

    6. Juni 20253 Views

    Whoop wants everyone to give a whoop about the new Whoop 5.0

    1. Juni 20253 Views
    Stay In Touch
    • Facebook
    • YouTube
    • TikTok
    • WhatsApp
    • Twitter
    • Instagram
    Latest Reviews

    Subscribe to Updates

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    About Us

    Welcome to HealthRadar.net — your trusted destination for discovering the latest innovations in digital health. We are dedicated to connecting individuals, healthcare professionals, and organizations with cutting-edge tools, applications

    Most Popular

    New surgeon general nominee cofounded a16z backed health app with DOGE operative

    1. Juni 20254 Views

    RadNet Acquires See-Mode Technologies to Bolster AI Capabilities in Ultrasound Imaging

    6. Juni 20253 Views
    USEFULL LINK
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    QUICK LINKS
    • Ai
    • Gadgets
    • Health
    • News
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    Copyright© 2025 Healthradar All Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.